ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response

Autor: Cara Brodie, Danya Cheeseman, Dominique-Laurent Couturier, Sanjeev Kumar, Jason S. Carroll, Naomi Guppy, Kosuke Yusa, Evangelia K. Papachristou, Sankari Nagarajan, Jose-Enrique Gonzalez Prada, Carlos Caldas, Alejandra Bruna, Joseph Sutton, Shanade Dunn, Emily Archer Goode, Silvia-Elena Glont, Rachael Natrajan, Shalini V. Rao, Igor Chernukhin, Rasmus Siersbæk, Kamal Kishore, Chandra Sekhar Reddy Chilamakuri, Alasdair Russell

Publikováno v: Nature Genetics
Nature genetics
Nagarajan, S, Rao, S V, Sutton, J, Cheeseman, D, Dunn, S, Papachristou, E K, Prada, J G, Couturier, D, Kumar, S, Kishore, K, Chilamakuri, C S R, Glont, S, Archer Goode, E, Brodie, C, Guppy, N, Natrajan, R, Bruna, A, Caldas, C, Russell, A, Siersbæk, R, Yusa, K, Chernukhin, I & Carroll, J S 2020, ' ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response ', Nature Genetics, vol. 52, no. 2, pp. 187-197 . https://doi.org/10.1038/s41588-019-0541-5

Using genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screens to understand endocrine drug resistance, we discovered ARID1A and other SWI/SNF complex components as the factors most critically required for response to tw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8541d5c793f7939ad7f665331d15a4fc
https://pubmed.ncbi.nlm.nih.gov/32005967

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

Autor: Sarah-Jane Dawson, Sarah Bowden, Carlos Caldas, Bin Liu, Elena Provenzano, Paul D.P. Pharoah, Silvia-Elena Glont, Janet A. Dunn, Fiona M. Blows, Helena M. Earl, Louise Hiller, Christopher J. Poole, Ali Hr

Publikováno v: Annals of Oncology. 26:1488-1493

BACKGROUND: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predict whether patients are likely to respond to anti-PD-L1 therapies. To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba6043765d5cd4052e88635e0546fae
https://doi.org/10.1093/annonc/mdv192